Specialty Hub

In-depth learning materials and relevant resources by areas of interest.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

In this section

Cardiology

Assorted resources on conditions connected to Cardiology.

Dermatology

Latest information on diseases in Dermatology.

Endocrinology

A detailed look at conditions connected to Endocrinology.

Gastroenterology and Hepatology

In-depth material on Gastroenterology and Hepatology.

Haematology

Assorted resources on conditions connected to Haematology.

Immunology

Immunology, the immune system and immune-mediated diseases.

Infectious Diseases

A detailed look at conditions connected to Infectious Diseases.

Nephrology

Assorted resources on conditions related to Nephrology.

Neurology (CNS) and Pain

Learning materials and guidelines on Neurology (CNS) and Pain.

Oncology

A detailed look at conditions connected to Oncology.

Ophthalmology

Assorted resources on conditions connected to Ophthalmology.

Respiratory

In-depth material on Respiratory conditions.

Rheumatology

Latest information on diseases in Rheumatology.

Urology

Learning materials and guidelines on Urology.

Latest news

Drug news

FDA lifts clinical hold on investigational lenacapavir for the treatment and prevention of HIV.

Gilead Sciences, Inc. announced the FDA has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP).

1 mins

Drug news

Update on CheckMate -901 trial evaluating Opdivo + Yervoy as first-line treatment for metastatic urothelial carcinoma

Bristol Myers Squibb announced the Phase III CheckMate -901 trial, comparing Opdivo (nivolumab) plus Yervoy (ipilimumab) to standard-of-care chemotherapy as a first-line treatment for patients with untreated unresectable or metastatic urothelial carcinoma, did not meet the primary endpoint of overall survival (OS) in patients whose tumor cells express PD-L1 greater than 1% at final analysis.

1 min

Drug news

Results from a Pylarify AI study presented at the American Urological Association (AUA) Annual Meeting.

Lantheus Holdings, Inc. presented results from a retrospective analysis of quantitative Pylarify (piflufolastat F18) PSMA (prostate specific membrane antigen) scan indices as a response imaging-biomarker to androgen deprivation therapy in veterans with newly diagnosed metastatic prostate cancer.

1 min

See all news

You may be interested in...

Guideline

The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma

Objective: This overview presents the updated European Association of Urology (EAU) guidelines for metastatic urothelial carcinoma.

Learning Zone

Anti-TNF biosimilars for rheumatic diseases

Explores unmet needs in rheumatic disease management, including inequities in treatment access, and how anti-TNF biosimilars can help to address this gap.

Guideline

Asia Pacific Glaucoma Guidelines

The Asia Pacific Glaucoma Guidelines have been produced by the APGS to assist ophthalmologists throughout the region to optimally manage patients with glaucoma using the world’s best current knowledge and standards.